A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Those with type 2 diabetes mellitus \& essential hypertension
• Those who agree to discontinue existing antihypertensive and/or oral hypoglycemic drugs during the clinical trial
• Those who are judged medically reasonable by investigator to be able to discontinue existing antihypertensive and/or oral hypoglycemic drugs(except for Metformin) during the clinical trial
Locations
Other Locations
Republic of Korea
Severance Hospital
RECRUITING
Seoul
Severance Hospital
RECRUITING
Seoul
Contact Information
Primary
Shin-young Oh
syoh@boryung.co.kr
+82-2-708-8000
Time Frame
Start Date: 2024-05-21
Estimated Completion Date: 2025-04
Participants
Target number of participants: 276
Treatments
Experimental: BR1019A + BR1019B + BR1019C-1
Active_comparator: BR1019A + BR1019B-1 + BR1019C-1
Active_comparator: BR1019A-1 + BR1019B + BR1019C-1
Other: BR1019A-1 + BR1019B + BR1019C
Related Therapeutic Areas
Sponsors
Leads: Boryung Pharmaceutical Co., Ltd